A PHASE 1B/2 MULTICENTER OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC) IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) (IDeate-Lung03)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lung Cancer
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line therapy
    2. Has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR, PR, or SD
    3. Has received no prior treatment for ES-SCLC

You may not be eligible for this study if the following are true:

    1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd
    2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities
    3. Has received prior treatment with CD137 agonists or ICIs, including anti- cytotoxic T-cell lymphocyte-4 (CTLA-4), anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.